Paris +

Colin Devinant's practice centers on national and international patent litigation. He has experience working on contentious and noncontentious matters in France and abroad (Germany, U.S., UK) for start-up and international groups involving patent rights across many technical fields (mechanics, chemistry, electronics, cosmetics, packaging, transports, consumer products, medical devices, agrochemical products, construction, biosimilars, and generics).

Colin's primary focus is on patent validity and infringement litigation as well as on compensation for employee inventions and patent ownership claims. He regularly drafts and negotiates confidentiality, license, research, and technology transfer agreements and also performs IP due diligence in support of M&A and private equity deals.

Prior to joining Jones Day in 2018, Colin practiced patent litigation and IP due diligence in the Paris office of a U.S.-based international law firm and interned at a leading French patent litigation firm in Paris. His previous experience also includes serving as an intern in the IP legal department of a leading French research university, where he drafted and negotiated R&D agreements, as well as for a French patent and trademark prosecution firm.

Colin has authored several publications discussing patent litigation, notably regarding software patents, generics, and the Unified Patent Court.

Colin is a member of the International Association for the Protection of Intellectual Property (AIPPI) and the French Association for the Protection of Intellectual Property (AFPPI).

He is a lecturer at the Cape Sup intensive bar exam program in Lyon, where he is in charge of preparing trainee-lawyer candidates for the final English oral exam.


  • Elephant participates in €30 million Series B financing round of DataDomeJones Day represented Elephant as lead investor in the €30 million Series B round of financing of DataDome, a French leading bot protection vendor.
  • French biotech company seeks to audit and to improve existing trade secret protection policyJones Day is advising a French biotechnology company with respect to auditing and improving its existing trade secret protection policy.
  • Aurora Resurgence sells Alltub Group to One Equity PartnersJones Day advised Aurora Resurgence in the sale of portfolio company Alltub Group to One Equity Partners.
  • New Alpha participates in €4 million financing round of Fred de la comptaJones Day advised New Alpha Asset Management in connection with the €4 million (US$4.6 million) round of financing of Fred de la compta, a company providing a platform and data analysis tools in the field of accounting.
  • Additional Publications

    Publications Prior to Jones Day


    Combination of active ingredients – scope of protection – Gilead

    December 2017

    UPC: a French perspective

    March 2017

    The Impending Launch of the Unified Patent Court